SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on February 27, 2003; DOI 10.1182/blood-2002-12-3842. This Article Full Text (PDF) All Versions of this Article: 2002-12-3842v1 102/1/53    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Spaepen, K. Articles by Verhoef, G. Search for Related Content PubMed PubMed Citation Articles by Spaepen, K. Articles by Verhoef, G. Related Collections Related Article in Blood Online Social Bookmarking                   What's this? Submitted December 19, 2002 Accepted February 15, 2003 Prognostic value of pretransplant positron emission tomography using fluorine18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation Karoline Spaepen, Sigrid Stroobants, Patrick Dupont, Peter Vandenberghe, Johan Maertens, Guy Bormans, Jose Thomas, Jan Balzarini, Christine De Wolf-Peeters, Luc Mortelmans*, and Gregor Verhoef Department of Nuclear Medicine, UZ Gasthuisberg, Leuven, Belgium Department of Oncology, UZ Gasthuisberg, Leuven, Belgium Department of Hematology, UZ Gasthuisberg, Leuven, Belgium Department of Pathology, UZ Gasthuisberg, Leuven, Belgium KULeuven, Rega Institute, Leuven, Belgium * Corresponding author; email: luc.mortelmans{at}uz.kuleuven.ac.be. Objectives: The study was intended to assess the prognostic value of fluorine-18 fluoro-deoxyglucose positron emission tomography ([18F]FDG-PET) after salvage chemotherapy before high dose chemotherapy with stem cell transplantation (HDT/SCT) in induction failure or relapsing chemosensitive lymphoma patients. Methods: Retrospective analysis of the clinical- and conventional imaging data of 60 patients scheduled for HDT/SCT, was performed in parallel with the analysis of the [18F]FDG-PET results. To determine the ability of [18F]FDG-PET to predict clinical outcome, PET images were re-read without knowledge of conventional imaging and/or clinical history. Presence or absence of abnormal [18F]FDG-uptake was related to progression-free survival (PFS) and overall survival (OS) using Kaplan-Meier survival analysis. Results: Thirty patients showed a negative [18F]FDG-PET scan before HDT/SCT; 25 of those remained in a complete remission, with a median follow-up of 1510 days. Two patients died due to a treatment related mortality but without evidence of recurrent disease at that time (228-462 days). Only 3 patients relapsed (median PFS, 1200 days) after a negative [18F]FDG-PET scan. Persistent abnormal [18F]FDG-uptake was seen in 30 patients and 26 progressed (median PFS 402 days) of which 16 died from progressive disease (median OS 408 days). Four patients are still in a complete remission after a positive scan. Comparison between groups indicated a statistically significant association between [18F]FDG-PET findings and PFS (p<0.000001) and OS (p<0.00002). Conclusion: [18F]FDG-PET has an important prognostic role in the pretransplantation evaluation of lymphoma patients and enlarges the concept of chemosensitivity used to select patients for HDT/SCT. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Positron emission tomography predicts transplantation outcome David James Inwards Blood 2003 102: 2. [Full Text] [PDF] This article has been cited by other articles: M. Hutchings and S. F. Barrington PET/CT for Therapy Response Assessment in Lymphoma J. Nucl. Med., May 1, 2009; 50(Suppl_1): 21S - 30S. [Abstract] [Full Text] [PDF] S. Ben-Haim and P. Ell 18F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response J. Nucl. Med., January 1, 2009; 50(1): 88 - 99. [Abstract] [Full Text] [PDF] A V Martin and B Sharma Positron emission tomography and CT in the management of lymphoma Imaging, September 1, 2008; 20(3): 169 - 175. [Abstract] [Full Text] [PDF] M. Soudack, R. B. Shalom, O. Israel, Y. Ben-Arie, Z. Levy, and D. Gaitini Utility of Sonographically Guided Biopsy in Metabolically Suspected Recurrent Lymphoma J. Ultrasound Med., February 1, 2008; 27(2): 225 - 231. [Abstract] [Full Text] [PDF] S. Sasaki, N. Shikama, K. Koiwai, and M. Kadoya Relationship Between the Response to Treatment and the Prognosis of Patients with Aggressive Lymphomas Treated with Chemotherapy Followed by Involved-field Radiotherapy: Radiographic Assessment Jpn. J. Clin. Oncol., January 1, 2008; 38(1): 43 - 48. [Abstract] [Full Text] [PDF] M. Crump Management of Hodgkin Lymphoma in Relapse after Autologous Stem Cell Transplant Hematology, January 1, 2008; 2008(1): 326 - 333. [Abstract] [Full Text] [PDF] P. Seam, M. E. Juweid, and B. D. Cheson The role of FDG-PET scans in patients with lymphoma Blood, November 15, 2007; 110(10): 3507 - 3516. [Abstract] [Full Text] [PDF] P. Toma, C. Granata, A. Rossi, and A. Garaventa Multimodality Imaging of Hodgkin Disease and Non-Hodgkin Lymphomas in Children RadioGraphics, September 1, 2007; 27(5): 1335 - 1354. [Abstract] [Full Text] [PDF] M. E. Juweid, S. Stroobants, O. S. Hoekstra, F. M. Mottaghy, M. Dietlein, A. Guermazi, G. A. Wiseman, L. Kostakoglu, K. Scheidhauer, A. Buck, et al. Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma J. Clin. Oncol., February 10, 2007; 25(5): 571 - 578. [Abstract] [Full Text] [PDF] B. D. Cheson, B. Pfistner, M. E. Juweid, R. D. Gascoyne, L. Specht, S. J. Horning, B. Coiffier, R. I. Fisher, A. Hagenbeek, E. Zucca, et al. Revised Response Criteria for Malignant Lymphoma J. Clin. Oncol., February 10, 2007; 25(5): 579 - 586. [Abstract] [Full Text] [PDF] B. W. Schot, J. M. Zijlstra, W. J. Sluiter, G. W. van Imhoff, J. Pruim, W. Vaalburg, and E. Vellenga Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma Blood, January 15, 2007; 109(2): 486 - 491. [Abstract] [Full Text] [PDF] P. Venugopal and S. A. Gregory Lymphoproliferative disorders ASH Self-Assessment Program, January 1, 2007; 2007(1): 265 - 297. [Full Text] [PDF] Y. L. Kasamon, R. J. Jones, and R. L. Wahl Integrating PET and PET/CT into the Risk-Adapted Therapy of Lymphoma J. Nucl. Med., January 1, 2007; 48(1_suppl): 19S - 27S. [Abstract] [Full Text] [PDF] F. Cachin, H. M. Prince, A. Hogg, R. E. Ware, and R. J. Hicks Powerful Prognostic Stratification By [18F]Fluorodeoxyglucose Positron Emission Tomography in Patients With Metastatic Breast Cancer Treated With High-Dose Chemotherapy J. Clin. Oncol., July 1, 2006; 24(19): 3026 - 3031. [Abstract] [Full Text] [PDF] V. Kalff, C. Duong, E. G. Drummond, J. P. Matthews, and R. J. Hicks Findings on 18F-FDG PET Scans After Neoadjuvant Chemoradiation Provides Prognostic Stratification in Patients with Locally Advanced Rectal Carcinoma Subsequently Treated by Radical Surgery J. Nucl. Med., January 1, 2006; 47(1): 14 - 22. [Abstract] [Full Text] [PDF] W A Weber PET for response assessment in oncology: radiotherapy and chemotherapy Br. J. Radiol., November 1, 2005; Supplement_28(1): 42 - 49. [Abstract] [Full Text] [PDF] W. A. Weber Use of PET for Monitoring Cancer Therapy and for Predicting Outcome J. Nucl. Med., June 1, 2005; 46(6): 983 - 995. [Abstract] [Full Text] [PDF] G. J. Kelloff, J. M. Hoffman, B. Johnson, H. I. Scher, B. A. Siegel, E. Y. Cheng, B. D. Cheson, J. O'Shaughnessy, K. Z. Guyton, D. A. Mankoff, et al. Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development Clin. Cancer Res., April 15, 2005; 11(8): 2785 - 2808. [Abstract] [Full Text] [PDF] T. Kazama, S. C. Faria, V. Varavithya, S. Phongkitkarun, H. Ito, and H. A. Macapinlac FDG PET in the Evaluation of Treatment for Lymphoma: Clinical Usefulness and Pitfalls RadioGraphics, January 1, 2005; 25(1): 191 - 207. [Abstract] [Full Text] [PDF] R. Munker, J. Glass, L. K. Griffeth, T. Sattar, R. Zamani, M. Heldmann, R. Shi, and D. L. Lilien Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease Ann. Onc., November 1, 2004; 15(11): 1699 - 1704. [Abstract] [Full Text] [PDF] B. D. Cheson What Is New in Lymphoma? CA Cancer J Clin, September 1, 2004; 54(5): 260 - 272. [Abstract] [Full Text] [PDF] R. M. Meyer, R. F. Ambinder, and S. Stroobants Hodgkin's Lymphoma: Evolving Concepts with Implications for Practice Hematology, January 1, 2004; 2004(1): 184 - 202. [Abstract] [Full Text] [PDF] J. W. Friedberg and V. Chengazi PET Scans in the Staging of Lymphoma: Current Status Oncologist, October 1, 2003; 8(5): 438 - 447. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020